Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Capital Expenditures data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 74.64% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (down 96.89% YoY), and the FY2025 full-year result was $7.7 million, down 87.74% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.9 million, up from $5000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $42.3 million in Q4 2022 and bottomed at -$3.2 million in Q3 2022.
• The 5-year median for Capital Expenditures is $7.2 million (2024), against an average of $10.3 million.
• Peak annual rise in Capital Expenditures reached 726.57% in 2022, while the deepest fall reached 157.98% in 2022.
• A 5-year view of Capital Expenditures shows it stood at $42.3 million in 2022, then plunged by 91.85% to $3.4 million in 2023, then jumped by 297.85% to $13.7 million in 2024, then slumped by 99.96% to $5000.0 in 2025, then surged by 38560.0% to $1.9 million in 2026.
• The last three Capital Expenditures figures came in at $1.9 million (Q1 2026), $5000.0 (Q4 2025), and $38000.0 (Q2 2025), per Business Quant data.

Peer Comparison